anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The investigators will recruit male Tajik migrants who inject drugs from 12 different sites in Moscow, including bazaars and other work sites. In both study arms, the recruited men (index participants) will be required to recruit two eligible MWID peers for interviews prior to being interviewed themselves. Participants will be randomly assigned to either the peer educator intervention program or the health education intervention program. After peer-recruited network members are enrolled and interviewed, the index participant will participate in the peer educator training or the control group activities. All participants and recruited network members will then be followed and re-interviewed at 3-month intervals for one year to assess changes in risky drug, alcohol, and sexual behaviors due to intervention participation and through diffusion to network members. The investigators will also collect data from voluntary HIV and HCV testing conducted at 6 months (HCV only) and at 12 months (HIV and HCV) post-intervention.
The present invention discloses the applications of a low molecular polypeptide ZY4 in preparing drugs for anti- acnes , anti-infection, anti-cancer and cosmetics. The low molecular polypeptide ZY4 comprises 17 amino acid residues, with a molecular weight of 2374.0 Da, an isoelectric point of 10.74, and an amino acid sequence of SEQ ID NO:1. The low molecular polypeptide ZY4 in the invention is artificially synthesized, with the advantages of small molecular weight and convenient artificial synthesis. The experiments have showed that the polypeptide ZY4 has obvious antibacterial effect and has significant therapeutic effect on  acnes . The polypeptides can inhibit the growth of tumor cells and kill the tumor cells. The low molecular polypeptide ZY4 can be used in the preparation of medicaments or cosmetics having the effect of anti-infective, anti-tumor or anti-acne.
The invention concerns polysaccharides which are cross-linked with bi-functional cross-linking agents, no longer water-soluble although still bio-degradable, and swell by between 100 and 1000 %, the swelling, which is defined as the percentage weight increase, being determined by the equation: A = Gt? - Go? / Go? x 100 wherein: A represents the percentage weight increase, Go? the weight of the dry polymer, and Gt? the weight of the swollen, water-saturated polymer. The invention also concerns a method for the production of the cross-linked polysaccharides and the use thereof for coating or embedding pharmacologically active substances or pharmaceuticals. The invention further concerns a medicament containing a substance either coated with or embedded in one of the cross-linked polysaccharides which acts in the colon or one which can be broken down while passing through the stomach or small intestine.
Patients received PCI (recommended hippocampal protection) within 6 weeks after first-line treatment, with a total dose of 25 Gy, 2.5 Gy each time, once a day, 5 times a week, a total of 10 times. Brain enhancement MRI examination is performed every 3 months in first two years, and then performed every 6 months until the brain metastasis occur.
The esophageal cooling group adopts a new transesophageal cooling method, that is, an esophageal cooling catheter is placed after resuscitation in patients with cardiac arrest, and then a small temperature-controlled water circulation system is continuously perfused with 4℃ cold water. After the patient's body temperature reaches the target temperature of 33℃, the temperature is adjusted Control the water circulation system to maintain the target body temperature of (33±0.5)°C for 24 hours, and then reheat to (37±0.5)°C normal body temperature at a rate of 0.25-0.5°C/h and maintain it for 24 hours.
FIELD: organic chemistry, medicine, dermatology. SUBSTANCE: invention relates to compounds of the formula (I)   and their pharmaceutically acceptable salts and esters where Ar represents phenyl group that can be optionally substituted with from 1 to 3 substituents taken among the group consisting of halogen atoms and trifluoromethyl groups. These compounds show an antifungal activity. Compounds show the enhanced antifungal activity. EFFECT: valuable medicinal properties of compounds. 15 cl, 3 tbl
FIELD: biotechnology, medicinal microbiology. SUBSTANCE: strain Bifidobacterium bifidum N 791/BAG is obtained by selection of the strain B. bifidum N 791. Selection is carried out without use of any chemical and physical mutagens by a long time by turn culturing in two different nutrient media: Blaurock's medium and sterile defatted milk without growth factors for 50 passages by morphocultural criterions. Strain is more resistant to impairment factors of cultured media and aggressive media of human gastroenteric tract, it provides utilization of the more broad spectrum of amino acids, i. e. it shows the more high viability and colonizing properties that provides preparing preparations and foodstuffs on its base with the more long storage time and the more high curative-prophylactic properties. Invention can be used for preparing liquid concentrate of bifidobacteria and fermented- -milk curative-dietetic foodstuffs and bifido-containing bifidobacteria biologically active additions based on liquid concentrate of bifidobacteria. EFFECT: strain of bacterium indicated above, valuable properties. 10 tbl, 7 ex
The process of insertion and removal of urinary catheterization was first explained to the students in the control group by the instructor of the course in the research team by demonstrations on the models. Then, each student was allowed to perform the application. Then, all students were invited again 15 days later for the second application. In both applications, the students were evaluated independently by the researchers.
BACKGROUND: A new model of care enables French physiotherapists (PT) working in collaboration with family physicians (FP) to expand their usual scope of practice for patients with acute low back pain (LBP). The aim of our study is to evaluate the impact of this new first-contact physiotherapy (FCP) advanced practice model compared to usual FP care.
METHODS: A multicentre pragmatic non-inferiority cluster randomised controlled trial (RCT) has been conducted in six multidisciplinary primary healthcare centres in France. Patients from 20 to 55 years old with acute LBP consulted either the PT or the FP. PT independently assessed and managed patients including medication prescription. The primary outcome measure was disability at six weeks (Roland Morris Disability Questionnaire, range 0-24). Secondary outcomes include pain, risk disability prognosis, satisfaction with care, healthcare resources use and wait times. Data were collected at baseline, six and twelve weeks. Outcomes across arms were compared using mixed models regression analysis. Except for non-inferiority analysis of the primary outcome measure, other analyses were performed with a two-sided significance level of 0.05.
RESULTS: Sixty patients were recruited (PT: 32, FP: 28). The adjusted mean difference between groups for disability at 6 weeks was 0.39 in favour of the FP group (95%CI: -2.03; 2.81, p = 0.753). Considering a 5 points minimal clinically important difference, the FCP-led model of care was not inferior to usual FP care for the primary outcome. There was no statistically significant difference between groups in disability at 3 months and pain at 6 weeks and 3 months. PTs prescribed significantly less medications than FPs (p < 0.001). No statistically significant difference was found for other healthcare resource use outcomes, patients' satisfaction and wait times.
CONCLUSION: This is the first RCT to evaluate the impact of a FCP advanced practice model of care including medical delegated acts in a primary care setting. Our results suggest that the FCP-led model of care is not inferior to usual FP care regarding disability at 6 weeks. The FCP model could result in possible benefits in terms of healthcare resources use. Further adequate powered studies with larger sample size are needed to draw stronger conclusions.
TRIAL REGISTRATION: The study has been registered in ClinicalTrials.gov (NCT05200533) on the 20th of January 2022.
PROBLEM TO BE SOLVED: To obtain a rhigotic composition especially for lip, capable of enhancing an effect for providing the cold feeling without increasing a formulating amount of a material for providing the cold feeling, excellent in feeling in use and hardly stimulating the sin by using two kinds of specific materials providing cold feeling in combination. SOLUTION: This rhigotic composition is obtained by formulating one or more kinds of polyhydric alcohols having endothermic heat of dissolution in water, and one or more kinds of menthol derivatives. The polyhydric alcohols are preferably erythritol and/or fructose. The menthol derivative is preferably 3-1-menthoxypropane-1,2-diol. The formulating amount of the polyhydric alcohols in the composition is preferably 0.01-10wt.%, and that of the menthol derivative is preferably 0.01-5wt.%. The composition is suitable for a rouge, a lipstick, etc.
INTRODUCTION: Estimated blood loss (EBL) is an important part of the perioperative process. This project aims to determine the accuracy of perioperative team members to estimate blood volume on drapes and the operating room floor.
METHODS: Aliquots of unused human blood were used to create surgical scenarios, and standardized pictures and videos were taken. Physicians, residents, nurses, medical students, and surgical technicians were surveyed and asked to estimate the blood volume for each series. Accuracy and consistency of responses was analyzed.
RESULTS: One hundred and forty five responses were recorded: 57 attending physicians, 36 residents, 27 registered nurses, 17 medical students, and seven circulating surgical techs. Median percent error (PE) for all cases was 211.11%, demonstrating a global overestimation of blood volume. PE for the 150 mL images was statistically significantly lower than that of the 50 and 100 mL images. Circulating Surgical Technicians were the most accurate group, with a median PE of 125%, followed closely by Medical Students (PE = 158.33%). The most accurate specialty was Orthopedics (PE = 168.06%). The least accurate groups were Attending Physicians (PE = 286.11%) and General surgery (GSGY) (PE = 327.78%). The most accurate orthopedic surgery and GSGY subspecialties were Hand (PE = 237.64%) and Vascular (PE = 108.33%), respectively. Statistical analyses showed no significant differences by clinical role, surgical specialty, or subspecialty.
CONCLUSION: This study demonstrates a global overestimation of blood volume when using the visual method, with improved accuracy at higher volumes. Our findings highlight the limitations of visual estimation methods for EBL.
No fertility medication. Crossover participants who choose to crossover after the 3 month follow up visit will restart follow up as per the Device arm.
Provided is a method of collecting and managing information relating to medical diagnostic procedures which includes collecting objective information about a plurality of procedures and subjective information about the results of those procedures. The objective information provides information about the parameters of the procedure and the patient who underwent the procedure while the subjective information includes an assessment of the quality of the results of the procedure. This information can be stored in a database. The database can be accessed and the information therein used in connection with understanding the results of past procedures and planning for future procedures. _____ ____ ____5/23 -K 0 0 w w z oo z _ _ Lai CCS>, 0 An '-B 0p. CIE Ez I 1 00 c4j ta
ABSTRACT      An agent suitable for intravascular administration comprising a suspension of minute particles, is provided, said particles having a size such that subsequent to their intravascular administration they block the finer blood vessels of the body.  The suspension is more stable than those previously available, and not as subject to sedimentation.  The particles of the suspension decompose in sufficient time to avoid the serious consequences arising from a prolonged blockage of the blood vessels.  In addition, the suspension is resistant to heat and fluctuations in temperature.           The agent consists of a suspension of minute particles which comprise a polysaccharide built up of glucose units or a physiologically acceptable derivative of said polysaccharide in a physiologically acceptable aqueous liquid.  The particles comprise a water-insoluble, but hydrophilic, swellable, three-dimensional network of molecules of the polysaccharide, or of the derivative thereof, cross-linked by means of bridges having bonds of a covalent nature.  Said network may be broken up by x-anylase in blood plasma into water-soluble fragments within a time after injection that can be varied within wide limits.           The agent is produced by suspending the minute particles in a physiologically acceptable aqueous liquid.
<P>PROBLEM TO BE SOLVED: To provide a dental prosthesis having adequate strength and high safety and excellent in affinity/contactness for oral mucous membrane.  <P>SOLUTION: The dental prosthesis consists mainly of a plastic material. A saponified product (EVOH) of an ethylene-vinyl ester copolymer is used as the plastic material. The EVOH is a resin having merits having good hydrophilicity and having good contactness with oral mucous membrane, because the EVOH is swollen by saliva in oral cavity and excellent in safety, because the EVOH has adequate hardness and does not discharge a component poisonous to human bodies even by heating or hydrolysis, etc. and excellent in moldability because of thermoplastic resin. The dental prosthesis is particularly used as a denture base or a mooring member for denture base.  <P>COPYRIGHT: (C)2008,JPO&INPIT
In children and adolescents, bipolar disorder is often accompanied by symptoms such as hallucinations, delusions, or paranoia that require acute treatment with a combination of an atypical antipsychotic medication and a mood stabilizer. It is not known if it is necessary to continue treatment with the atypical antipsychotic medication after the child's symptoms have remitted.

Participants in this study are treated with lithium, divalproex (Depakote), and one of the following atypical antipsychotic medications: olanzapine (Zyprexa), risperidone (Risperdal) or quetiapine (Seroquel) for at least 24 weeks. Participants who have already begun combination therapy with at least one of the mood stabilizers and atypical antipsychotic medications listed above are also encouraged to enroll in this study. After participants have been on combination therapy for at least 24 weeks they will then be randomly assigned to one of two groups. The first group will continue to receive active mood stabilizer and atypical antipsychotic medication. The second group will receive active mood stabilizer and placebo. Participants are assessed weekly and followed for up to 18 months.
Placebo. Saline (NaCl), 200 μl for intranasal administration, 2 dosing occasions.
Obesity, characterised by excessive fat accumulation, is a complex chronic condition that results from dysfunctional adipose tissue expansion due to prolonged calorie surplus. This leads to rapid adipocyte enlargement that exceeds the support capacity of the surrounding neurovascular network, resulting in increased hypoxia, inflammation, and insulin resistance. Intermittent fasting (IF), a dietary regimen that cycles between periods of fasting and eating, has emerged as an effective strategy to combat obesity and improve metabolic homeostasis by promoting healthy adipose tissue remodeling. However, the precise molecular and cellular mechanisms behind the metabolic improvements and remodeling of white adipose tissue (WAT) driven by IF remain elusive. This review aims to summarise and discuss the relationship between IF and adipose tissue remodeling and explore the potential mechanisms through which IF induces alterations in WAT. This includes several key structural changes, including angiogenesis and sympathetic innervation of WAT. We will also discuss the involvement of key signalling pathways, such as PI3K, SIRT, mTOR, and AMPK, which potentially play a crucial role in IF-mediated metabolic adaptations.
The study included 60 patients at high risk for PONV (Apfel-score 0, I, II, III and IV) scheduled for elective laparoscopic surgeries at the Central Surgical Center of Irmandade da Santa Casa de Misericórdia in São Paulo. Inclusion criteria will be ASA I or II of either sex, in the age range of 18 to 70 years. In this study, the recruited patients will be allocated randomly into three groups. The group A will receive oral 600 mg gabapentin 2 h before surgery. The group B will receive oral 150 mg pregabalin 2 h before surgery. The Group C will receive oral placebo 2 h before surgery and ondansetron 8mg intravenous at the end of the surgery. This study is "double-blind", in which neither the doctor nor the patient knows what medicine is being given.
Artesunate 50 mg orally, daily for 4 days. Vitamin A 5000IU orally daily for 4 days if \< 1 year. 10,000IU orally daily for 4 days if \> 1 year.
The high-risk features of plaque rupture and subsequent acute coronary syndrome (ACS) are not fully identified. Plaque features, hemodynamic forces, and the interaction between these factors may cause plaque instability and subsequent clinical events. A previous study showed that the addition of hemodynamic parameters calculated noninvasively from coronary computed tomography (CCTA) using computational fluid dynamics (such as wall shear stress and axial plaque stress) improved the ability to predict the risk of ACS compared with conventional approaches based on anatomical stenosis severity and adverse plaque characteristics. Wall shear stress and axial plaque stress derived from CT were highly correlated to those derived from optical coherence tomography (OCT). In addition, other hemodynamic parameters, such as oscillatory shear index, endothelial shear stress (ESS), and spatial ESS gradient have also been demonstrated to be associated with unstable plaque. In this regard, we designed this study to find the best hemodynamic and plaque features derived from CTA and verified by OCT to predict ACS, and to investigate whether a comprehensive risk prediction model with them has an incremental value in a larger population.
The present invention discloses and claims a functionally active peptide of VEGF of SEQUENCE ID NO.: 3 through primers for RT-PCR for cloning the c-DNA obtained from VEGF, comprising a forward primer of 28 bp under SEQUENCE ID NO.: 2 and the reverse primer under SEQUENCE ID NO.: 1 of 32 bp. In addition, the present invention discloses a process of preparation of VEGF comprising the steps of isolating the RNA of VEGF (SEQUENCE ID NO.: 3); RT-PCR of VEGF using primers of SEQUENCE ID NO.: 1 and 2, and collecting the purified c DNA; ligating the clones as obtained with the vector pTZ57R/T; preparing the competent cells; transforming the cloned cells after selecting through antibiotic resistance in vector; isolating the protein obtained; and purifying said obtained VEGF protein.
Subjects will consume all meals/snacks during a \~15-h daily eating period (\~9-h fasting). The prescribed energy intake will be monitored and adjusted as needed to achieve weight maintenance.
Although the underlying mechanisms of fatigue have been studied in several disease conditions the data are not conclusive, and this symptom remains poorly managed at present. Longitudinal studies related to treatment-related fatigue in prostate cancer patients have been conducted, but there are limited studies exploring the changes in physiologic mechanisms before and after radiotherapy which can identify individuals who are at risk for enduring fatigue during and after therapy. Fatigue is conceptualized as a multidimensional symptom which incorporates temporal, sensory, cognitive/mental, affective/emotional, behavioral, and physiological dimensions. This prospective, observational study is the first study to explore the molecular-genetic mechanisms underlying fatigue and the cluster of symptoms (urinary, sexual, gastrointestinal, psychiatric) experienced by prostate cancer patients undergoing External Beam Radiation Therapy (EBRT).

The primary objective of the study is to describe the changes in the self-reported fatigue; urinary, sexual, and gastrointestinal symptoms; depression; fatigue catastrophizing; and health-related quality of life (HRQOL) experienced by patients with and without prostate surgery before, during, and after EBRT completion. The secondary objectives of this study are to investigate the pro-inflammatory cytokine profile of EBRT-related fatigue (TNF alpha, IGF-I, IL-6, IL-8, TGF alpha and beta), determine changes in white blood cell gene expression, determine levels of oxidative stress and changes in potential biomarkers influencing oxidative stress from blood and buccal samples before and after EBRT completion and to relate these changes in the levels of these biological markers to self-reported fatigue; urinary, sexual, and gastrointestinal symptoms; depression; fatigue catastrophizing; and HRQOL scores. This study also aims to measure the skeletal muscle strength, activity/fitness levels, cognitive function and energy expenditure of patients before, at completion of EBRT, and at least 6 months post EBRT and relate these findings with self-reported fatigue, physical symptoms (e.g. urinary, gastrointestinal, and sexual functioning), depression, and HRQOL scores before and after an exercise training program. The study also aims to describe changes in chemical profile in the brain that are associated with changes in fatigue symptoms using magnetic resonance spectroscopy before and after EBRT.
PURPOSE: To identify the effects of Rho Kinase (ROCK) inhibitor medications on human orbital adipogenesis, fibroblast proliferation, and fibrosis.
METHODS: Orbital adipose tissue was obtained from patients with Graves' ophthalmopathy (GO) as well as controls (non-GO or normal) after informed consent was done. These tissue samples were cultured and adipogenesis was initiated. Levels of Rho Kinase as well as cellular mediators of orbital inflammation and fibrosis. The same cultures and measurements were then repeated with the use of a ROCK inhibitor (KD025-ROCK2) to assess for changes in adipogenesis as well as markers associated with inflammation and fibrosis.
RESULTS: Rho Kinase levels in GO tissue were more highly expressed than in controls. These levels were suppressed with the use of the ROCK inhibitor KD025. There was a dose-dependent reduction in differentiation of orbital adipocytes with the use of KD025. KD025 reduced the levels of fibrosis-related gene expression. Finally, there was a significant reduction of transforming growth factor beta mediated phosphorylation signaling pathways in the KD025-treated GO tissue.
CONCLUSION: This study shows that the ROCK inhibitor, KD025, helps to reduce the expression of ROCK in GO tissue along with reducing orbital adipocyte differentiation as well as cell mediators involved in fibrosis that occurs in GO.
The recommended dosage of TRUSELTIQ is 125 mg (one 100 mg capsule and one 25 mg capsule) orally once daily for 21 consecutive days followed by 7 days off therapy, in 28-day cycles. Continue treatment until disease progression or unacceptable toxicity.

Instruct patients to take TRUSELTIQ on an empty stomach at least 1 hour before or 2 hours after food [ seeClinical Pharmacology(12.3) ], at approximately the same time each day. Instruct patients to swallow capsules whole with a glass of water. Advise patients to not crush, chew, or dissolve capsules. 

If a dose of TRUSELTIQ is missed by ≥4 hours or if vomiting occurs, instruct patients to resume the regular daily dose schedule for TRUSELTIQ the next day.